Once thought to be purely an endocrine disorder, a more modern understanding of insulin resistance and glycemic regulation has revealed that prediabetes, type 1 and type 2 diabetes are hugely related to cardiometabolic disease and its many comorbidities. As the understanding of how diabetes is related to conditions like obesity and heart failure grows, more therapeutic targets are being identified, showing promise for many new treatments.
Dr. Salvatore Carbone is professor in the Department of Kinesiology & Health Sciences, College of Humanities & Sciences at the Virginia Commonwealth University. Can you
Cardiometabolic health education leader CMHC announced that its digital education has been streamlined into 12 hubs organized by therapeutic or clinical topics for focused learning
In August 2023, Cardiometabolic Health Congress will host the annual Women’s Cardiometabolic Health and Wellness Masterclass at the Laguna Cliffs Marriott Resort & Spa Informed
Cardiometabolic Health Congress (CMHC) sat down with Dr. Keith C. Ferdinand, the Gerald S. Berenson Endowed Chair in preventive cardiology at Tulane School of Medicine
The new ADA guideline contains updated guidance for clinicians who care for the estimated 100 million patients in the U.S. with prediabetes or diabetes.
Hypoglycemia is estimated to affect 47-83% of patients with diabetes and is a common side effect of several diabetes medications, but is particularly associated with
This complimentary activity was developed by Neha Agarwal, PhD, Senior Clinical Manager for Cardiometabolic Health Congress (CMHC). It is supported by an educational grant from Lilly
The U.S. Food and Drug Administration (FDA) announced on May 26, 2023, it had approved the once-daily oral tablet sotagliflozin to reduce the risk of
The experts behind Cardiometabolic Health Congress have identified 10 stories in cardiorenal medicine to watch in 2023.
Sanofi was the last of three pharmaceutical goliaths to announce they’d make good on their long-spoken promise to lower the price of their insulin.
Research published on Feb. 20, 2023, by Rafiqul Islam, PhD, and colleagues from Queensland University of Technology may have uncovered a concrete link between blood
In an era when health care and pharmaceutical prices continue to trend upwards, Eli Lilly made a historic announcement on Wednesday, March 1, 2023, stating
Eli LIlly’s tirzepatide (Monjaro) could become the most popular weight-loss drug ever if approved, but there are significant concerns about if it will be affordable
On Jan. 12, 2023, Novo Nordisk announced the US Food and Drug Administration (FDA) approved a label update to permit first-line use of oral semaglutide
The experts at Cardiometabolic Health Congress (CMHC) have selected the TOP 10 developments, approvals, news, and findings from 2022 that impact the field of cardiorenal
The FDA has approved Eli Lilly’s insulin glargine-aglr, sold under the brand name Rezvoglar.
Researchers have found consuming certain forms of honey may improve glycemic control and lipid levels when part of a healthy dietary pattern.
For the first time in history, the FDA has approved a therapy that addresses the autoimmunity behind T1D — not just the symptoms of the
(Recorded April 2022)
(Recorded April 2022)
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Cardiometabolic Health Congress
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2023, Cardiometabolic Health Congress. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
